



Tel. direct: +41 22 791 33 76
Fax direct: +41 22 791 47 30
E-mail : sabartovaj@who.int

In reply please
refer to: P5-447-3/JS/SC

Dr R. E. Santing
Proxy Laboratories B.V.
Archimedesweg 25-27
NL-2333 CM Leiden,
Pays-Bas

Your reference:

18 August 2011

Dear Dr Santing,

**WHO Prequalification of Medicines Programme
Prequalification of Quality Control Laboratories
Proxy Laboratories B.V., Leiden, The Netherlands**

This is in reference to our letter dated 25 February 2010 expressing the interest of Proxy Laboratories B.V., Leiden, The Netherlands to participate in the Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies.

Thank you for submitting the data and information requested during the procedure and for the cooperation within the inspection.

We are pleased to inform you that Proxy Laboratories B.V., Leiden, The Netherlands is considered to be operating at an acceptable level of compliance with WHO Good Practices for Pharmaceutical Quality Control Laboratories (GPCL) and will be included in the list of prequalified quality control laboratories together with the areas of expertise inspected and considered prequalified (see Annex 1).

You can access the information on the prequalification procedure, as well as the list of prequalified quality control laboratories, on the Programme's web-site at www.who.int/prequal. We would like to remind you of the General Notes and Disclaimer which were communicated to you previously and can also be found on the same web-site.

cc: EURO

ENCL. (2)

1. Area of expertise inspected and considered prequalified
2. Outline of the content of an annual report on activities of a prequalified laboratory

.../...

According to the procedure, each prequalified quality control laboratory should be routinely re-evaluated after its prequalification as well as on a non-routine basis. Therefore, all laboratories listed are requested to submit a brief annual report on its activities related to the quality control of medicines within a calendar year by the end of March of the following year at the following address:

Dr Jitka Sabartova
World Health Organization
HSS/EMP/QSM Room M627
20 Avenue Appia
1211 Geneva 27, Switzerland
sabartovaj@who.int

For the content of this report, please see Annex 2. Further, should any changes be implemented that may have significant impact on the prequalification of the laboratory, WHO should be informed without delay.

We should like to take this opportunity to thank you for your cooperation.

Yours sincerely,



Dr Lembit Rāgo
Coordinator
Quality Assurance and Safety: Medicines